Potential Interaction of Propyl Gallate and Butylated Hydroxyanisole with EGFR–PI3K–Akt–mTOR Proteins in Oral and Gastrointestinal Carcinogenic Signaling Pathway: An in silico Molecular Docking Study
Abstract
BACKGROUND: Synthetic food preservatives are widely used to improve food stability and shelf life, but prolonged exposure may contribute to oral and gastrointestinal carcinogenesis. Epidermal growth factor receptor (EGFR)–phosphoinositide 3-kinase (PI3K)–protein kinase B (Akt)–mammalian target of rapamycin (mTOR) axis plays a pivotal role in regulating tumor initiation and progression; however, the potential interactions with cancer-related signaling proteins remain poorly understood. This study computationally evaluated the predicted binding interactions of commonly used synthetic food preservatives with proteins using molecular docking.
METHODS: Propyl gallate (PG), butylated hydroxyanisole (BHA), tertiary-butylhydroquinone (TBHQ), potassium sorbate (PS), sodium benzoate (SB), and sodium metabisulfite (SMB) were evaluated for physicochemical properties using SwissADME. Molecular docking with EGFR, PI3K, Akt-1, and mTOR was performed using CB-Dock 2.0. Predicted ligand–protein interactions were analyzed using BIOVIA Discovery Studio 2016 and root mean square fluctuation (RMSF) was evaluated using CABS-flex 3.0.
RESULTS: PG and BHA exhibited the most predicted binding affinities among the investigated preservatives. PG showed the strongest interactions with EGFR (−6.1 kcal/mol), PI3K (−6.8 kcal/mol), and mTOR (−6.7 kcal/mol), whereas BHA demonstrated the highest affinity toward PI3K (−6.8 kcal/mol) and Akt-1 (−6.5 kcal/mol). These interactions were supported by multiple hydrogen bonds, hydrophobic interactions, and van der Waals contacts.
CONCLUSION: PG and BHA exhibited the highest binding affinity toward proteins of the EGFR–PI3K–Akt–mTOR associated with oral and gastrointestinal carcinogenesis. These computational findings provide a basis for future experimental studies to determine the biological relevance of the predicted protein–ligand interactions under long-term dietary exposure.
KEYWORDS: synthetic food preservatives, molecular docking, oral carcinogenesis, gastrointestinal carcinogenesis
Full Text:
PDFReferences
Chauhan K, Rao A. Clean-label alternatives for food preservation: An emerging trend. Heliyon. 2024; 10(16): e35815, CrossRef.
Ji X, Liu J, Liang J, Feng X, Liu X, Wang Y, et al. The hidden diet: Synthetic antioxidants in packaged food and their impact on human exposure and health. Environ Int. 2024; 186(2024): 108613, CrossRef.
Chen J, Xia P. Health effects of synthetic additives and the substitution potential of plant-based additives. Food Res Int. 2024; 197: 115177, CrossRef.
Shi J, Xu J, Liu X, Goda AA, Salem SH, Deabes MM, et al. Evaluation of some artificial food preservatives and natural plant extracts as antimicrobial agents for safety. Discov Food. 2024; 4(1): 89, CrossRef.
Iqbal MJ, Kabeer A, Abbas Z, Siddiqui HA, Calina D, Sharifi-Rad J, et al. Interplay of oxidative stress, cellular communication and signaling pathways in cancer. Cell Commun Signal. 2024; 22(1): 7, CrossRef.
Li P, Qu R, Li M, Sheng P, Jin L, Huang X, Xu ZZ. Impacts of food additives on gut microbiota and host health. Food Res Int. 2024; 196 (114998): 1-59, CrossRef.
Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked?. Free Radical Biol Med. 2010; 49(11): 1603-16, CrossRef.
Moloney JN, Cotter TG. ROS signalling in the biology of cancer. Semin Cell Dev Biol. 2018; 80: 50-64, CrossRef.
Schiliro C, Firestein BL. Mechanisms of metabolic reprogramming in cancer cells supporting enhanced growth and proliferation. Cells. 2021; 10(5): 1056, CrossRef.
Sajadimajd S, Khazaei M. Oxidative stress and cancer: the role of Nrf2. Curr Cancer Drug Targets. 2018; 18(6): 538-57, CrossRef.
Ionescu C, Kamal FZ, Ciobica A, Halitchi G, Burlui V, Petroaie AD. Oxidative stress in the pathogenesis of oral cancer. Biomedicines. 2024; 12(6): 1150, CrossRef.
Glaviano A, Foo AS, Lam HY, Yap KC, Jacot W, Jones RH, et al. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023; 22(1): 138, CrossRef.
Noorolyai S, Mokhtarzadeh A, Baghbani E, Asadi M, Baghbanzadeh KA, Mogaddam MM, et al. The role of microRNAs involved in PI3‐kinase signaling pathway in colorectal cancer. J Cell Physiol. 2019; 234(5): 5664-73, CrossRef.
Safitri PGA, Da'i M, Wulandari F. 1'-Acetoxychavicol acetate suppresses osteosarcoma cell proliferation through the PI3K pathway: A molecular docking and cytotoxicity study. Mol Cell Biomed Sci. 2025; 9(2): 105-14, CrossRef.
Morgos DT, Stefani C, Miricescu D, Greabu M, Stanciu S, Nica S, et al. Targeting PI3K/AKT/mTOR and MAPK signaling pathways in gastric cancer. Int J Mol Sci. 202425(3): 1848, CrossRef.
Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V, Gutkind JS. Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol. 2009; 45(4-5): 324-34, CrossRef.
Rahaju P, Kintono RA, Wahyudiono AD, Satria A, Sandra F. Immunohistochemical expression of EGFR, NF-kB and cyclin D1 in sinonasal inverted papilloma and squamous cell carcinoma. Indones Biomed J. 2020; 12(3): 239-44, CrossRef.
Rajendran P, Sekar R, Dhayasankar PS, Ali EM, Abdelsalam SA, Balaraman S, et al. PI3K/AKT signaling pathway mediated autophagy in oral carcinoma-a comprehensive review. Int J Med Sci. 2024; 21(6): 1165-75, CrossRef.
Demir K, Turgut R, Şentürk S, Işıklar H, Günalan E. The therapeutic effects of bioactive compounds on colorectal cancer via PI3K/Akt/mTOR signaling pathway: a critical review. Food Sci Nutr. 2024; 12(12): 9951-73, CrossRef.
Rizal MI, Sandra F. Brucea javanica leaf extract activates caspase-9 and caspase-3 of mitochondrial apoptotic pathway in human oral squamous cell carcinoma. Indones Biomed J. 2016; 8(1): 43-8, CrossRef.
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Revi. 2001; 46(1-3): 3-26, CrossRef.
Daina A, Michielin O, Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports. 2017; 7: 42717, CrossRef.
Leemans CR, Snijders PJ, Brakenhoff RH. The molecular landscape of head and neck cancer. Nat Rev Cancer. 2018; 18(5): 269-82, CrossRef.
Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer. 2017; 17(2): 79-92, CrossRef.
Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K pathway in human disease. Cell. 2017; 170(4): 605-35, CrossRef.
Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014; 505(7484): 495-501, CrossRef.
Hanker AB, Kaklamani V, Arteaga CL. Challenges for the clinical development of PI3K inhibitors: Strategies to improve their impact in solid tumors. Cancer Discov. 2019: 9(4): 482-91, CrossRef.
Manning BD, Toker A. AKT/PKB Signaling: Navigating the Network. Cell. 2017; 169(3): 381-405, CrossRef.
Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR Signaling in Cancer. Fronts Oncol. 2014; 4: 64, CrossRef.
Leiphrakpam PD, Batra R, Tenner L, Are C. Targeting Akt signaling pathway in cancer: molecular mechanisms and advances in therapeutic interventions. Front Biosci. 2025; 30(11): 39100, CrossRef.
Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017; 168(6): 960-76, CrossRef.
Hua H, Kong Q, Zhang H, Wang J, Luo T, Jiang Y. Targeting mTOR for cancer therapy. J Hematol Oncol. 2019; 12(1): 71, CrossRef.
Zheng S, He S, Liang Y, Tan Y, Liu Q, Liu T, et al. Understanding PI3K/Akt/mTOR signaling in squamous cell carcinoma: Mutated PIK3CA as an example. Mol Biomed. 2014; 5(1): 13, CrossRef.
Tjingson N, Rizal MI, Sandra F. The tumor microenvironment of oral squamous cell carcinoma: Cellular components and their therapeutic targets. Mol Cell Biomed Sci. 2026; 10(2): 82-92, CrossRef.
Massardi A, Bahry SS, Rahmawati NA, Shabirah CA, Pangastuti A. Bioactive compounds from Penicillium sp. inhibit antiapoptotic Bcl-2, Bcl-XL and Mcl-1: An in silico study. Mol Cell Biomed Sci. 2023; 7(2): 81-9, CrossRef.
DOI: https://doi.org/10.18585/inabj.v18i4.4329
Copyright (c) 2026 The Prodia Education and Research Institute

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute